Parkinson's Priority Therapeutic Clinical Pipeline Report

This report tracks therapies currently in clinical development for Parkinson’s disease as of late March 2024. It includes brief rationale and progress in key pipelines of therapeutic interest along with detailed listings of specific therapies, current development status and information about MJFF support (funding and/or non-funding connections).

MJFF monitors numerous sources to assess the therapeutic pipeline. These include online intelligence databases (e.g., Citeline, clinicaltrials.gov), company websites and our own direct engagement with industry sponsors. While the report is extensive, it is not comprehensive of every intervention in development for Parkinson’s disease. Rather, it represents treatments identified by MJFF as important given potential significance to the Parkinson’s community and for understanding MJFF role and impact. 

This report is updated and distributed on an annual basis, although pipeline data are tracked regularly, and we may generate supplements to the report as needed. Information in this report is considered non-confidential, intended only as a guide for communicating pipeline progress and does not represent endorsement by MJFF of specific therapies. Any errors or omissions are not intentional.